Oncology

Coverage from the Institute for Value-Based Medicine event with Vanderbilt University Medical Center.

Coverage from the Institute for Value-Based Medicine session with Florida Cancer Specialists & Research Institute.

There is bipartisan support in the Congress for the Community Oncology Alliance's (COA) key agenda items, with hope that some will pass by year’s end.

Ted Okon, MBA, executive director, Community Oncology Alliance, discusses early returns from the Enhancing Oncology Model and how community oncology practices are innovating in ways that can expand into other areas of medicine.

Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance, discusses the challenges facing oncology today, such as physician and nurse recruitment and minority clinical trial enrollment.

At the 2023 COA Payer Exchange Summit being held October 23-24 in Reston, Virginia, Lalan Wilfong, MD, US Oncology Network, emphasizes the importance of oncology care equity, ensuring continuity of care, and enhancing care coordination.

Adding pembrolizumab to combination of trastuzumab and chemotherapy improved progression-free survival vs placebo plus trastuzumab and chemotherapy in the first-line treatment of patients with metastatic HER2-positive gastric or gastroesophageal junction (GEJ) cancer.

A 2022 yearlong initiative at Summa Health Cancer Institute saw 100% of its patients with head and neck cancer undergoing radiation treatment referred to an oncology dietician for nutritional support and/or speech and swallow therapy.

Knowledge of the different treatment options available and the eligibility criteria for each will help identify the right treatment for patients with hepatobiliary cancer.

The survey, completed over 2 weeks in September, follows a similar one released in June.

Adults with cancer may have difficulty self-assessing the clinical severity of their acute care needs, yet they rarely use a telephone triage line available to them.

Enrollment in managed care among Medicaid enrollees presents challenges to classifying Medicaid coverage in cancer registries.

Carmen Solórzano, MD, FACS, of Vanderbilt University Medical Center, discusses how Vanderbilt-Ingram Cancer Center (VICC) conducts tumor boards and explains how patient preferences are considered during them.

In 2023, the United States was in the midst of the largest drug shortage in a decade, including lifesaving platinum-based medications to treat a variety of cancers.

Crystal Denlinger, MD, FACP, incoming CEO of the National Comprehensive Cancer Network (NCCN), talks about the organization’s challenges and solutions to keeping up with the ever-changing oncology landscape and improving patient access to guideline-recommended treatments.

Denlinger, who spent most of her career at Fox Chase Cancer Center before joining the National Comprehensive Cancer Network (NCCN) as its chief scientific officer, took the helm October 9, 2023.

Gustavo Fonseca, MD, FACP, physician director of clinical research, Florida Cancer Specialists & Research Institute (FCS), discusses the results from a late phase complexity analysis on barriers to clinical trials regarding biopsy requirements.

Coverage from the June 8, 2023, Institute for Value-Based Medicine session in Austin, Texas, held in partnership with Texas Oncology.

Coverage from the June 8, 2023, Institute for Value-Based Medicine session in Austin, Texas, held in partnership with Texas Oncology.

New research demonstrated varying trends in early-onset cancer incidence based on race, sex, age, and cancer type.

One in 3 hospitals report issues with chemotherapy drug shortages; the suicide rate in the United States hit an all-time high in 2022; an acid reflux medication may be linked with higher risk of dementia.

Even after adjustments, the underlying trends in disparities persisted, underscoring the significance of survival disparities among second primary cancer survivors.

Using data from the Swedish National Medical Birth Register, researchers found that different neurocutaneous syndromes are associated with increased risk of childhood cancer, especially central nervous system tumors.

In his explanation of the tremelimumab priming dose, Ghassan Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, also reviews and analogizes checkpoint inhibitors as a whole.

Coverage of clinical trial results presented across a range of solid tumor cancers, including breast, ovarian, colorectal, and non-small cell lung cancer, among other types; as well as important findings in genomic testing.

Coverage of addresses by ASCO President Eric P. Winer, MD, and National Cancer Institute Director Monica M. Bertagnolli, MD, who is a former ASCO president.

Ghassan Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, expands on findings that durvalumab plus tremelimumab demonstrated an overall survival benefit at 4 years for certain patients with unresectable hepatocellular carcinoma.